Top Ten most popular articles on Pharmafile.com this week
pharmafile | December 13, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | pharma, top ten
As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and will hold government for at least the next five years, check out our run-down of the top 10 most popular stories on Pharmafile.com this week.
10. South Korea jails executives for their role in Samsung Biologics fraud
Three executives of Samsung Electronics have been sentenced to jail for their role in committing fraud at its biotech affiliate Samsung Biologics.
AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax in combination with rituximab (VenR) in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
8. Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia
Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data on its candidate CC-486 in the maintenance treatment of front-line, newly diagnosed acute myeloid leukaemia (AML) in patients who have achieved remission with intensive induction chemotherapy.
7. FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis
The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult patients for relapsing multiple sclerosis (MS).
6. Anti-vaxx movement complicit in 140,000 global measles deaths in 2018, mostly in children
Over 140,000 people died from measles last year, with most of them being children under five, according to World Health Organization (WHO) and the US Centers for Diseases Control and Prevention.
5. FDA investigating if carcinogen NDMA is in diabetes drug
The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical.
4. Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019
Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone (D-VMP) in the treatment of newly diagnosed, transplant-ineligible multiple myeloma at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando.
3. Sanofi acquires biotech firm Synthorx for $2.5 billion
Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion).
2. Sanofi to move away from diabetes and cardiovascular, as company shakeup continues
Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the company’s ongoing internal review.
1. Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels
Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients with haemophilia A through to 44 weeks following treatment.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
